GlassScriptPhysician profile
Daisy Zevallos
NPI 1093433088
$4,575.33
in general payments reported to CMS, 2019-2025
20 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Registered Nurse) providers received nationally (typical 2025 total: $137).
See the full distribution for Psychiatric/Mental Health (Registered Nurse)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.50 · 2023: $1,023 · 2024: $1,751 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,529.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $888.67 | 2023-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $519.55 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $420.81 | 2023-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $392.56 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $344.33 | 2024-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $313.09 | 2024-2025 | Auvelity |
| Corium, LLC | $295.56 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $233.29 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $231.46 | 2022-2025 | Caplyta |
| Tris Pharma INC | $200.47 | 2024-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Lundbeck LLC | $144.43 | 2023-2025 | Rexulti |
| Alkermes, INC. | $102.46 | 2022-2025 | Lybalvi, Aristada |
| Collegium Pharmaceutical, INC. | $91.72 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $86.09 | 2024-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $72.22 | 2023-2024 | Jornay Pm |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $67.02 | 2024-2025 | Ingrezza |
| Bausch Health US, LLC | $60.23 | 2024-2025 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $57.04 | 2023-2025 | Xelstrym, Secuado |
| Vertical Pharmaceuticals, LLC | $37.68 | 2025 | Relexxii |
| Acadia Pharmaceuticals INC | $16.65 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Zevallos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.